Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) is on recovery track with 31.11% gain from a 1-year low price of $1.1. The company added 5.36% to attain the price of $1.18 on Sep. 12, 2017. Throughout the recent session, the prices were hovering between $1.11 and $1.22. These shares are 465.25% off its target price of $6.67 and the current market capitalization stands at $20.47M. The recent change has given its price a -0.65% deficit over SMA 50 and -69.74% deficit over its 52-week high. The stock witnessed 14.56% gains, -5.6% declines and -54.79% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found EYEG’s volatility during a week at 8.31% and during a month it has been found around 7.94%.

Eyegate Pharmaceuticals, Inc. (EYEG) Top Holders

Institutional investors currently hold around $3 million or 39.5% in EYEG stock. Look at its top three institutional owners. Armistice Capital, Llc owns $1.81 million in Eyegate Pharmaceuticals, Inc., which represents roughly 8.84% of the company’s market cap and approximately 60.33% of the institutional ownership. Similar statistics are true for the second largest owner, Sabby Management, Llc, which owns 345,524 shares of the stock are valued at $387 thousand. The third largest holder is Vanguard Group Inc, which currently holds $277 thousand worth of this stock and that ownership represents nearly 1.35% of its market capitalization.

Eyegate Pharmaceuticals, Inc. 13F Filings

At the end of June reporting period, 5 institutional holders increased their position in Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) by some 1,965,674 shares, 6 decreased positions by 54,513 and 5 held positions by 214,215. That puts total institutional holdings at 2,234,402 shares, according to SEC filings. The stock grabbed 2 new institutional investments totaling 1,961,524 shares while 4 institutional investors sold out their entire positions totaling 43,868 shares.

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Insider Trades

Multiple company employees have indulged in significant insider trading. Eyegate Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Interim CFO Romano Sarah has acquired 10,000 shares of Eyegate Pharmaceuticals, Inc. (EYEG) in trading session dated Aug. 15, 2017. These shares are worth $10,000 and were traded at $1 each. The SEC filing shows that From Stephen performed a purchase of 12,500 shares. The President and CEO added these shares by way of transaction on Aug. 10, 2017. The company’s shares were assimilated at $1.03 per share worth to an investment of some $12,875 on account of From Stephen.

10% Owner, Ventech Capital Ii, sold 4,419 common shares of Eyegate Pharmaceuticals, Inc. (EYEG) in the open market. In a transaction dated Mar. 13, 2017, the shares were put up for sale at an average price of $2.8, raking in a sum of $12,373. After this sale, 1,431,814 common shares of EYEG are directly owned by the insider, with total stake valued at $1,689,541.

In the transaction dated Mar. 06, 2017, the great number of shares disposed came courtesy the Director; Goldberg Morton disposed a total of 8,919 shares at an average price of $3, amounting to approximately $26,757. The insider now directly owns 9,441 shares worth $11,140.

Eyegate Pharmaceuticals, Inc. (EYEG) Analyst Guide

Several analysts have released their opinion on Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG), with 3 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.

Previous articleIndia Globalization Capital, Inc. (IGC) added to 3 new portfolios
Next articleGlobal X Management Co Llc is the biggest holder of Uranium Energy Corp. (UEC)